Services

Liver Alert

Sign up to receive E-mail notifications when fresh hepatocytes become available.Register now.

Request a Quote

Contact one of our service professionals for a fast and reliable quote. Get started.

Calendar of Events

Date Event Name
May 26 - 28, 2013 DDI Marbach Castle Conference

Drug Transporters

 

Helpful links for your convenience:

Download XenoTech's guide to Drug Transporter Studies here, or view the online ebook.

View some common Transporter study Q&A here.

View XenoTech's transporter assay decision tree here.

______________________________________________________________________________

Transporters Overview

Drugs that are substrates or inhibitors of drug transporters have been implicated in drug-drug interactions. The 2012 FDA DDI draft guidance and the 2012 EMA guideline on investigation of drug interactions mention several specific transporters to investigate and assay conditions to follow. XenoTech’s experimental approach conforms to these scientific principles in evaluating test articles as Inhibitors and Substrates of Human P-gp, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, OCT1 and OCT2 transporters.

All of XenoTech’s methods are state of the art and based on established scientific practices. For substrate studies, an LC/MS method will be developed for the analysis of each test article with a minimum of a single curve will be analyzed to establish dose response prior to the analysis of the study samples. XenoTech’s LC/MS (Analytical) group gives Transporter assays fast turnaround with same day assays.

______________________________________________________________________________

XenoTech Transporter Services Benefits:

  • In collaboration with Sekisui Medical, XenoTech is able to offer the widest selection of transporter assays on the market
  • Assays available for all transporters mentioned in the FDA and EMA guidance documents
  • Assays available for an extensive variety of non-FDA/EMA transporters, including exotic transporters expressed in oocytes
  • In vivo studies available for a wide variety of transporters
  • Studies are performed in a GLP-compliant facility and governed by XenoTech's in-house Quality Assurance Unit
  • Ability to perform FDA/EMA submission studies with radiolabeled compounds or cold compounds due to XenoTech’s in-house Analytical Sciences group
  • Ability to perform transporter substrate studies with complicated bioanalytics due to XenoTech’s in-house Analytical Sciences group
  • Ability to deliver submission-ready reports due to XenoTech's in-house Knowledge Management group
  • Ability to meet strict timelines, deliver industry-leading scientific quality and maintain unsurpassed levels of communication and trust

______________________________________________________________________________

EMA / FDA Transporter Assays Available

XenoTech offers the full array of EMA/FDA recommended transporters.

In accordance with the 2012 EMA guidance, XenoTech evaluates intestinal permeability as outlined below.

Test System Model Assay
Caco-2 Intestinal Permeability Model - Substrate Bidirectional permeability of TA across monolayer

 
XenoTech offers the following Substrate transporter evaluation assays.

Test System Transporter(s) Assay
MDCKII-MDR1 P-gp (MDR1) Bidirectional permeability of TA across monolayer
MDCKII-BCRP BCRP Bidirectional permeability of TA across monolayer
HEK293 OATP1B1, OATP1B3, OCT1, OCT2 Accumulation of TA in transporter-expressing cells
S2 OAT1, OAT3 Accumulation of TA in transporter-expressing cells

 
XenoTech offers the following Inhibitor transporter evaluation assays.

Test System Transporter(s) Assay
Caco-2 P-gp Bidirectional permeability of probe substrate in the presence of TA
MDCKII-MDR1 P-gp (MDR1) Bidirectional permeability of probe substrate in the presence of TA
MDCKII-BCRP BCRP Bidirectional permeability of probe substrate in the presence of TA
HEK293 OATP1B1, OATP1B3, OCT1, OCT2 Accumulation of probe substrate in the presence of TA
S2 OAT1, OAT3 Accumulation of probe substrate in the presence of TA

*Cell toxicity is assessed by measuring the lactate dehydrogenase (LDH) released from the cells, using unexposed media as a background control.